Jose Alejandro Rauh-Hain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jose Alejandro Rauh-Hain has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Roni Nitecki Wilke
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
12 shared publications - Alexander Melamed
Massachusetts General Hospital, Boston, MA
11 shared publications - David M. Boruta
Massachusetts General Hospital/Harvard University, Boston, MA, USA
10 shared publications - Marcela G. del Carmen
Oslo, Norway
10 shared publications Roni Nitecki
University of Texas MD Anderson Cancer Center, Houston, TX, United States
10 shared publicationsAlexander Melamed
Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston
9 shared publications
Latest Publications
- 24 March 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 207, A1-A2
Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection
- 24 March 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 207, A1-A2
Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection
- Top Cited PapersOpen Access
- 4 November 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (11) , e2446325
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer
Cytoreductive surgery, either as the primary treatment or after neoadjuvant chemotherapy (NACT), for advanced epithelial ovarian cancer (EOC), fallopian tube carcinoma, and primary peritoneal cancer carries a substantial risk of complications1 that may hinder the timely administration of chemotherapy,2 lead to prolonged hospital stays and readmissions,3 and decrease survival.4 Although primary cytoreductive surgery followed by platinum-based adjuvant chemotherapy has been the standard-of-care treatment for advanced-stage EOC,5-7randomized clinical trials (RCTs) have demonstrated that administering NACT before cytoreductive surgery can reduce surgical morbidity and improve patients’ quality of life without compromising overall survival.8-14 Among patients who receive NACT, interval cytoreductive surgery performed with minimally invasive surgical techniques may further reduce morbidity.15-22 As the use of NACT has become increasingly common in the management of advanced-stage EOC,23,24 interval cytoreductive surgeries performed with minimally invasive techniques have also increased. By 2018, 29% of all interval cytoreductive surgeries conducted in Commission on Cancer–accredited cancer programs used a minimally invasive approach.24,25
- 4 November 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (11) , e2446325
Top Cited PapersOpen AccessLaparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer
Cytoreductive surgery, either as the primary treatment or after neoadjuvant chemotherapy (NACT), for advanced epithelial ovarian cancer (EOC), fallopian tube carcinoma, and primary peritoneal cancer carries a substantial risk of complications1 that may hinder the timely administration of chemotherapy,2 lead to prolonged hospital stays and readmissions,3 and decrease survival.4 Although primary cytoreductive surgery followed by platinum-based adjuvant chemotherapy has been the standard-of-care treatment for advanced-stage EOC,5-7randomized clinical trials (RCTs) have demonstrated that administering NACT before cytoreductive surgery can reduce surgical morbidity and improve patients’ quality of life without compromising overall survival.8-14 Among patients who receive NACT, interval cytoreductive surgery performed with minimally invasive surgical techniques may further reduce morbidity.15-22 As the use of NACT has become increasingly common in the management of advanced-stage EOC,23,24 interval cytoreductive surgeries performed with minimally invasive techniques have also increased. By 2018, 29% of all interval cytoreductive surgeries conducted in Commission on Cancer–accredited cancer programs used a minimally invasive approach.24,25
- Open Access
- 4 November 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (11) , 1677-1684
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion of patients into trials has been widely criticized for inadequate representation of the real-world population. Ideally, patients enrolled in clinical trials should represent a broader population to enhance external validity and facilitate translation of outcomes across all relevant groups. Specifically, there has been a systematic lack of data for underrepresented groups, with many studies failing to report or differentiate study participants based on sociodemographic domains, such as race and ethnicity. As such, the impact of treatment in these underrepresented groups is poorly understood, and clinical outcomes according to various sociodemographic factors are infrequently assessed. Inclusion of diverse trial participants, with different racial and ethnic background, is essential for the understanding of factors that may impact clinical outcomes. Therefore, we conducted a multi-national meeting of clinical trial groups and industry with the goal of increasing equity, diversity, and inclusion in gynecologic cancer clinical trials and to address barriers to recruitment, participation, and harmonization of data collection and reporting. These Gynecologic Cancer Intergroup (GCIG) statements present recommendations and strategies for the gynecologic cancer research community to improve equity, diversity, and inclusion in gynecologic cancer clinical trials.
- 4 November 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (11) , 1677-1684
Open AccessHow to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion of patients into trials has been widely criticized for inadequate representation of the real-world population. Ideally, patients enrolled in clinical trials should represent a broader population to enhance external validity and facilitate translation of outcomes across all relevant groups. Specifically, there has been a systematic lack of data for underrepresented groups, with many studies failing to report or differentiate study participants based on sociodemographic domains, such as race and ethnicity. As such, the impact of treatment in these underrepresented groups is poorly understood, and clinical outcomes according to various sociodemographic factors are infrequently assessed. Inclusion of diverse trial participants, with different racial and ethnic background, is essential for the understanding of factors that may impact clinical outcomes. Therefore, we conducted a multi-national meeting of clinical trial groups and industry with the goal of increasing equity, diversity, and inclusion in gynecologic cancer clinical trials and to address barriers to recruitment, participation, and harmonization of data collection and reporting. These Gynecologic Cancer Intergroup (GCIG) statements present recommendations and strategies for the gynecologic cancer research community to improve equity, diversity, and inclusion in gynecologic cancer clinical trials.
- Open Access
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Table 1: Interview Quotes
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Table 1: Interview Quotes
- Open Access
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Materials and Methods 1: Proband and Relative Interview Guide Documents
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Materials and Methods 1: Proband and Relative Interview Guide Documents
- Open Access
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Materials and Methods 1: Proband and Relative Interview Guide Documents
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Materials and Methods 1: Proband and Relative Interview Guide Documents
- Open Access
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Table 1: Interview Quotes
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
Supplementary Table 1: Interview Quotes
- Open Access
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured qualitative interviews were completed wherein patients shared their experiences with genetic counseling (GC), genetic testing (GT), and communicating their results to relatives. Relatives shared their experiences receiving information from the patient and considering CGT. Interviews were transcribed, coded, and themes were identified. Of 25 participating patients, most recalled key aspects of GC and their GT results. Most (80%) patients shared their results with relatives, but only some relatives underwent CGT; patients reported low perceived susceptibility to hereditary cancer as a common barrier to CGT for their relatives. Of 16 participating relatives, most reported feeling distress upon learning the patient's GT results. Relatives were fearful of learning their own CGT results but identified prevention and early detection as CGT benefits. Interviews identified opportunities during family communication to improve relatives’ perceived susceptibility to hereditary cancer. Tailored resources may support patients and relatives experiencing distress and fear during GT.Prevention Relevance:This study of intrafamilial communication and cascade genetic testing experiences of patients with hereditary cancer and their relatives from diverse, medically underserved populations identified relatives’ perceived susceptibility to hereditary cancer risks, distress, and fear as frequent reactions and barriers to testing. These results may inform future hereditary cancer prevention efforts.
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured qualitative interviews were completed wherein patients shared their experiences with genetic counseling (GC), genetic testing (GT), and communicating their results to relatives. Relatives shared their experiences receiving information from the patient and considering CGT. Interviews were transcribed, coded, and themes were identified. Of 25 participating patients, most recalled key aspects of GC and their GT results. Most (80%) patients shared their results with relatives, but only some relatives underwent CGT; patients reported low perceived susceptibility to hereditary cancer as a common barrier to CGT for their relatives. Of 16 participating relatives, most reported feeling distress upon learning the patient's GT results. Relatives were fearful of learning their own CGT results but identified prevention and early detection as CGT benefits. Interviews identified opportunities during family communication to improve relatives’ perceived susceptibility to hereditary cancer. Tailored resources may support patients and relatives experiencing distress and fear during GT.Prevention Relevance:This study of intrafamilial communication and cascade genetic testing experiences of patients with hereditary cancer and their relatives from diverse, medically underserved populations identified relatives’ perceived susceptibility to hereditary cancer risks, distress, and fear as frequent reactions and barriers to testing. These results may inform future hereditary cancer prevention efforts.
- Open Access
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured qualitative interviews were completed wherein patients shared their experiences with genetic counseling (GC), genetic testing (GT), and communicating their results to relatives. Relatives shared their experiences receiving information from the patient and considering CGT. Interviews were transcribed, coded, and themes were identified. Of 25 participating patients, most recalled key aspects of GC and their GT results. Most (80%) patients shared their results with relatives, but only some relatives underwent CGT; patients reported low perceived susceptibility to hereditary cancer as a common barrier to CGT for their relatives. Of 16 participating relatives, most reported feeling distress upon learning the patient's GT results. Relatives were fearful of learning their own CGT results but identified prevention and early detection as CGT benefits. Interviews identified opportunities during family communication to improve relatives’ perceived susceptibility to hereditary cancer. Tailored resources may support patients and relatives experiencing distress and fear during GT.Prevention Relevance:This study of intrafamilial communication and cascade genetic testing experiences of patients with hereditary cancer and their relatives from diverse, medically underserved populations identified relatives’ perceived susceptibility to hereditary cancer risks, distress, and fear as frequent reactions and barriers to testing. These results may inform future hereditary cancer prevention efforts.
- 4 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured qualitative interviews were completed wherein patients shared their experiences with genetic counseling (GC), genetic testing (GT), and communicating their results to relatives. Relatives shared their experiences receiving information from the patient and considering CGT. Interviews were transcribed, coded, and themes were identified. Of 25 participating patients, most recalled key aspects of GC and their GT results. Most (80%) patients shared their results with relatives, but only some relatives underwent CGT; patients reported low perceived susceptibility to hereditary cancer as a common barrier to CGT for their relatives. Of 16 participating relatives, most reported feeling distress upon learning the patient's GT results. Relatives were fearful of learning their own CGT results but identified prevention and early detection as CGT benefits. Interviews identified opportunities during family communication to improve relatives’ perceived susceptibility to hereditary cancer. Tailored resources may support patients and relatives experiencing distress and fear during GT.Prevention Relevance:This study of intrafamilial communication and cascade genetic testing experiences of patients with hereditary cancer and their relatives from diverse, medically underserved populations identified relatives’ perceived susceptibility to hereditary cancer risks, distress, and fear as frequent reactions and barriers to testing. These results may inform future hereditary cancer prevention efforts.
- 1 November 2023
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 17 (1) , 19-28
Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured qualitative interviews were completed wherein patients shared their experiences with genetic counseling (GC), genetic testing (GT), and communicating their results to relatives. Relatives shared their experiences receiving information from the patient and considering CGT. Interviews were transcribed, coded, and themes were identified. Of 25 participating patients, most recalled key aspects of GC and their GT results. Most (80%) patients shared their results with relatives, but only some relatives underwent CGT; patients reported low perceived susceptibility to hereditary cancer as a common barrier to CGT for their relatives. Of 16 participating relatives, most reported feeling distress upon learning the patient's GT results. Relatives were fearful of learning their own CGT results but identified prevention and early detection as CGT benefits. Interviews identified opportunities during family communication to improve relatives’ perceived susceptibility to hereditary cancer. Tailored resources may support patients and relatives experiencing distress and fear during GT. Prevention Relevance: This study of intrafamilial communication and cascade genetic testing experiences of patients with hereditary cancer and their relatives from diverse, medically underserved populations identified relatives’ perceived susceptibility to hereditary cancer risks, distress, and fear as frequent reactions and barriers to testing. These results may inform future hereditary cancer prevention efforts.
- 1 November 2023
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 17 (1) , 19-28
Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations—A Qualitative Study
We sought to explore the intrafamilial communication and cascade genetic testing (CGT) experiences of patients with hereditary cancer from diverse, medically underserved populations and their relatives. Participants included patients receiving oncology care at an urban, safety net hospital in Texas or comprehensive cancer center in Alabama and their first-degree relatives. In-depth semi-structured qualitative interviews were completed wherein patients shared their experiences with genetic counseling (GC), genetic testing (GT), and communicating their results to relatives. Relatives shared their experiences receiving information from the patient and considering CGT. Interviews were transcribed, coded, and themes were identified. Of 25 participating patients, most recalled key aspects of GC and their GT results. Most (80%) patients shared their results with relatives, but only some relatives underwent CGT; patients reported low perceived susceptibility to hereditary cancer as a common barrier to CGT for their relatives. Of 16 participating relatives, most reported feeling distress upon learning the patient's GT results. Relatives were fearful of learning their own CGT results but identified prevention and early detection as CGT benefits. Interviews identified opportunities during family communication to improve relatives’ perceived susceptibility to hereditary cancer. Tailored resources may support patients and relatives experiencing distress and fear during GT. Prevention Relevance: This study of intrafamilial communication and cascade genetic testing experiences of patients with hereditary cancer and their relatives from diverse, medically underserved populations identified relatives’ perceived susceptibility to hereditary cancer risks, distress, and fear as frequent reactions and barriers to testing. These results may inform future hereditary cancer prevention efforts.